NEW YORK (GenomeWeb) – The Federal Court of Australia today upheld an earlier judgment that Myriad Genetics could patent mutations in the BRCA1 gene that are linked to an increased risk of hereditary breast and ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.